

Commentary

Open Access

## Study designs of randomized controlled trials not based on Chinese medicine theory are improper

Jian Yan<sup>\*1</sup>, Veronica F Engle<sup>2</sup>, Yuxin He<sup>3</sup>, Yan Jiao<sup>4</sup> and Weikuan Gu<sup>4</sup>

Address: <sup>1</sup>Molecular Resource Center, University of Tennessee Health Science Center, Memphis, TN 38163, USA, <sup>2</sup>Department of Primary Care Nursing and Department of Preventive Medicine, University of Tennessee Health Science Center, Memphis, TN 38163, USA, <sup>3</sup>Acupuncture & Chinese Medical Center, Austin, TX 78757, USA and <sup>4</sup>Department of Orthopedics Surgery, University of Tennessee Health Science Center, Memphis, TN 38163, USA

Email: Jian Yan\* - jyan1@utmem.edu; Veronica F Engle - vengle@utmem.edu; Yuxin He - Dryuxinhe@yahoo.com; Yan Jiao - yjiao2@utmem.edu; Weikuan Gu - wgu@utmem.edu

\* Corresponding author

Published: 25 February 2009

Chinese Medicine 2009, 4:3 doi:10.1186/1749-8546-4-3

This article is available from: <http://www.cmjournal.org/content/4/1/3>

© 2009 Yan et al; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/2.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Received: 7 July 2006

Accepted: 25 February 2009

### Abstract

Current biomedical research methods to evaluate the efficacy of Chinese medicine interventions are often conceptually incompatible with the theory and clinical practice of Chinese medicine. In this commentary, we (1) highlight the theory and principles underlying Chinese medicine clinical practice; (2) use ginseng as an example to describe clinical indications in Chinese medicine; (3) propose a framework guided by Chinese medicine theory for the evaluation of study designs in Chinese medicine research; and (4) evaluate 19 randomized, double-blind, placebo-controlled trials of ginseng. Our analysis indicates that all 19 trials with both positive and negative results confirm the specific effects of ginseng indicated by Chinese medicine theory. Study designs guided by Chinese medicine theory are necessary to validate and improve future randomized controlled clinical trials in Chinese medicine.

### Background

Chinese medicine remains popular in China where traditional herbal preparations are estimated to account for 30–50% of the total medicinal consumption [1]. Chinese medicine has also been gaining popularity in the West [1–3]. However, Chinese medicine lacks funding and leading scientists to conduct scientific research (e.g. randomized controlled trials) [4].

The study of ginseng provides an example of the research challenges in Chinese medicine. Highly valued in the Chinese medicine classics and widely used in China for more than two thousand years, ginseng has yet to prove its safety and efficacy through clinical trials [5,6], which, many investigators believe, may be attributed to a para-

digm conflict and the poor quality of some clinical trials [7,8].

We found that this paradigm conflict may be resolved by using study designs guided by Chinese medicine theory.

### Chinese medicine theory

Chinese medicine is a syndrome-oriented holistic medical system that is conceptually distinct from its Western counterpart. According to Chinese medicine theory, a syndrome is a group of associated signs and symptoms described in terms of Yin and Yang, Qi, and Xue (blood) [9]. All illnesses fall into eight principal categories used to guide the prevention and treatment of illnesses [10]. These categories are Yin and Yang, Biao (exterior) and Li

(interior), *Han* (coldness) and *Re* (heat), and *Xu* (deficiency) and *Shi* (excess). Western medicine, however, views a disease or syndrome as pathological changes of specific biological processes [1]. As a result, the syndromes in Chinese medicine do not always correspond with Western classifications of diseases and syndromes. For instance, hypertension may be related to syndromes of *Gan* (liver) Yang ascending, Yin deficiency of liver and kidney, flaming liver fire, stagnation of phlegm, *Xue* stasis and/or dual Yin/Yang deficiency [11]. Conversely, *Qi*-deficiency syndrome is related to chronic obstructive pulmonary disease [12], lung cancer [13], coronary heart disease [14] and persistent allergic rhinitis [15].

#### **Herbal medications**

In Chinese medicine, medicinal herbs are categorized according to the concepts of Yin, Yang, *Qi*, *Xue*, *Jing* (essence) and *Jin* (body fluid) [16]. In general, 'tonics' are used to treat deficiency and 'clear-ups' are used to treat excess [9].

Considered the premium *Qi*-tonifying herb to treat various illnesses [16], ginseng is thought to have the major indications as follows:

- (1) Impalpable pulse caused by severe *Qi*-deficiency;
- (2) Shortness of breath, feeble voice, spontaneous sweating and a weak pulse caused by *Fei* (lung) *Qi*-deficiency;
- (3) Fatigue, anorexia and loose bowels caused by *Pi* (spleen) *Qi*-deficiency;
- (4) Fever and strong thirst caused by *Qi*-deficiency;
- (5) Palpitation, insomnia and forgetfulness caused by dual deficiency of *Qi* and *Xue*.

#### **Study design compatible with Chinese medicine theory**

##### **Research topics**

Instead of evaluating the efficacy of ginseng in all patients suffering from a single disease, researchers should focus on those patients with *Qi*-deficiency syndrome. *Qi*-deficiency causes decreased visceral functions and lowered immune resistance, leading to various diseases. The manifestations of *Qi*-deficiency include lassitude, shortness of breath, feeble voice, dizziness, spontaneous perspiration, susceptibility to cold, pale tongue and weak pulse [10].

##### **Participants**

Chinese medicine practitioners prescribe herbal medications to rectify disharmony in a patient's system [16]. Healthy individuals should not participate in treatment groups in Chinese medicine studies. This explains the negative results from the ginseng studies in which healthy individuals participated [17-21].

Ginseng is a *Qi*-tonifying herb to treat five major syndromes [16] caused by *Qi*-deficiency. Therefore, we argue that only studies in which participants are diagnosed with *Qi*-deficiency are valid to evaluate ginseng's efficacy [22-25].

#### **Herbal species**

While at least eight species of ginseng are commercially available [26], only two major species, namely *Panax ginseng* (Chinese or Korean ginseng) and *Panax quinquefolius* (American ginseng), are used as medicinal herbs worldwide. According to Chinese medicine theory, the properties and functions of these two species are quite different [16]. While *P. ginseng* enhances Yang, *P. quinquefolius* nourishes Yin. A search for randomized controlled trials of ginseng in PubMed (7 September 2008) found that about one-third of the studies did not mention the ginseng species used and that very few studies addressed the species issue.

#### **Herbal quality**

Herbal quality may affect research results. Different batches of *P. ginseng* [27,28] or *P. quinquefolius* [29] produced opposing study results respectively on acute post-prandial glycemia. The primary active ingredients in ginseng are ginsenosides. G115, a ginsenoside-based standardized extract of *P. ginseng*, may help assess the efficacy and safety of ginseng. In fact, G115 was used in most *P. ginseng* (single herb) trials reviewed in this paper.

#### **Herbal formulae**

In Chinese medicine, herbs are often formulated to achieve increased therapeutic effects and reduced toxicity or side effects [16]. Results from clinical trials on herbal formulae confirm this practice. A Japanese trial found that a 7-herb formula was effective in preventing liver cancer in cirrhosis patients [30]. Two British trials showed that a 10-herb formula was effective in treating a severe atop eczema [31,32]. No single herbal ingredient explains the efficacy in these studies [33]. Furthermore, ginseng herbal formulae were shown to be effective in treating chronic pulmonary disease [22,34], congenital heart disease [35,36], mild cognitive impairment [37], coronary heart disease [38] and nasopharyngeal carcinoma [39].

#### **Herbal safety**

Certain Chinese medicine herbs are toxic and others may have adverse effects when used improperly [16]. A condition known as the ginseng abuse syndrome is characterized by heart palpitations, heaviness in the chest, high blood pressure, dizziness, insomnia, agitation, restlessness, nausea, vomiting, abdominal pain and/or bloating, diarrhea, possible upper digestive tract bleeding, edema, and red skin rash [40]. Most of these reported adverse effects are common manifestations of *Qi*-excess and *Qi*-

stasis. While all clinical trials should document adverse effects, only one trial did do so [41].

#### **Re-examination of equivocal ginseng trial results**

To exemplify our framework of experimental study design, we searched and analyzed randomized controlled trials of ginseng in PubMed. The inclusion criteria were single herb ginseng trials with a sample size of  $\geq 20$ . We selected trials of single herb ginseng because the majority of the trials belonged to this category. Nineteen clinical trials were selected for analysis according to the inclusion criteria (Table 1) [42-46]. Most of the trials were considered good based on a trial quality evaluation scale [47].

#### **Research topic**

Out of the 19 trials, nine had negative results, ten had positive results, and none targeted ginseng's efficacy on *Qi*-deficiency syndromes.

#### **Participants**

Both healthy and unhealthy participants were evaluated for the effects of ginseng. Seven out of the nine trials with negative results involved healthy participants, whereas eight out of the ten studies with positive results had participants with *Qi*-deficiency manifested by cancer, impotence and pulmonary disease. Ellis *et al.* [48] investigated the time-dependent effects of *P. ginseng* on the quality of

**Table 1: Summary of results from single herb ginseng clinical trials**

	Trial quality*	Research topic	Participants (n)	Herb species	Chinese medicine theory	Reference
<b>Negative results</b>						
Allen JD <i>et al.</i> (1998)	4	Exercise performance	Healthy young (28)	<i>P. ginseng</i>	No <i>Qi</i> -deficiency	[17]
Cardinal BJ <i>et al.</i> (2001)	4	Psychological well-being	Healthy young adults (83)	<i>P. ginseng</i>	No <i>Qi</i> -deficiency	[18]
Caron MF <i>et al.</i> (2002)	3	Cardiovascular function	Healthy adults (30)	<i>P. ginseng</i>	No <i>Qi</i> -deficiency	[42]
Dowling EA <i>et al.</i> (1996)	3	Exercise performance	Highly trained distance runners (20)	<i>Acanthopanax senticosus</i>	No <i>Qi</i> -deficiency	[43]
Engels HJ <i>et al.</i> (1997)	3	Physiologic and psychological responses	Healthy adults (36)	<i>P. ginseng</i>	No <i>Qi</i> -deficiency	[21]
Engels HJ <i>et al.</i> (2001)	3	Exercise & short-term recovery	Healthy active women (24)	<i>P. ginseng</i>	No <i>Qi</i> -deficiency	[20]
Engels HJ <i>et al.</i> (2003)	3	Physical performance heart rate recovery	Active healthy adults (38)	<i>P. ginseng</i>	No <i>Qi</i> -deficiency	[19]
Stavro PM <i>et al.</i> (2006)	3	Blood pressure and renal function	Hypertension (52)	<i>P. quinquefolius</i>	Inappropriate herb species	[49]
Wiklund IK <i>et al.</i> (1999)	N/A	Quality of life & physiological parameters	Symptomatic postmenopausal women (384)	<i>P. ginseng</i>	Inappropriate herb species	[51]
<b>Positive results</b>						
Cicero AF <i>et al.</i> (2004)	2	Quality of life	Elderly hypertensive and digitalized (20)	<i>Acanthopanax senticosus</i>	Appropriate herb species	[53]
de Andrade E <i>et al.</i> (2007)	2	Sexual function	Erectile dysfunction (60)	<i>P. ginseng</i>	<i>Qi</i> -Deficiency	[44]
Ellis JM <i>et al.</i> (2002)	5	Quality of life	Healthy young (30)	<i>P. ginseng</i>	Marginal <i>Qi</i> -deficiency	[48]
Gross D <i>et al.</i> (2002)	N/A	Respiratory function	Chronic Obstructive Pulmonary Disease (COPD) (92)	<i>P. ginseng</i>	<i>Qi</i> -Deficiency	[22]
Hong B <i>et al.</i> (2002)	3	Sexual function	Erectile dysfunction (45)	<i>P. ginseng</i>	<i>Qi</i> -Deficiency	[45]
Kim JH <i>et al.</i> (2006)	3	Quality of life	Cancer (53)	<i>P. ginseng</i>	<i>Qi</i> -Deficiency	[23]
Liang MT <i>et al.</i> (2005)	3	Endurance exercise	Untrained adults (29)	<i>P. notoginseng</i>	Appropriate herb species	[54]
McElhaney JE <i>et al.</i> (2004)	3	Acute respiratory illness	Sub healthy seniors (198)	<i>P. quinquefolius</i>	<i>Qi</i> -Deficiency	[24]
McElhaney JE <i>et al.</i> (2006)	5	Acute respiratory illness	Sub healthy adults and seniors (43)	<i>P. quinquefolius</i>	<i>Qi</i> -Deficiency	[46]
Preedy GN <i>et al.</i> (2005)	5	Cold	Sub healthy adults (323)	<i>P. quinquefolius</i>	<i>Qi</i> -Deficiency	[25]

\*Trial quality evaluation scale [47]

0–2: poor quality

3–5: high quality

N/A: full text unavailable for quality evaluation

life in a healthy young adult population. In this case, the participants had marginal Qi-deficiency as young adults are at the stage of 'gradual filling of Qi and Xue' [9] according to Chinese medicine theory.

#### *Herbal species/safety*

The species of ginseng may be a confounding factor in the interpretation of trial results, which is illustrated by four trials as follows (Table 1).

Stavro *et al.* [40] enrolled 52 hypertensive participants to evaluate the long-term effects of *P. quinquefolius* on blood pressure [49]. Long-term use of ginseng was reported to be associated with the development of hypertension, which was refuted by Stavro *et al.* In Chinese medicine practice, however, *P. quinquefolius*, unlike its cousin *P. ginseng*, is in fact used to treat hypertension in some cases.

Wiklund *et al.* [50] reported a trial in which 384 symptomatic postmenopausal women were assessed for the effects of *P. ginseng* on the quality of life and physiological parameters. Postmenopausal symptoms such as hot flashes are often regarded as *Shen* (kidney) Yin-deficiency [51] and are treated with *P. quinquefolius* rather than *P. ginseng*. Moreover, the use of *P. ginseng* in this study was contraindicated and might have produced adverse effects.

Cicero *et al.* [52] studied 20 elderly hypertensive and digitalized patients treated with *Acanthopanax senticosus* (Siberian ginseng) which is a mild Qi-tonic for an unspecific feeling of fatigue, a sign of Qi-deficiency [53]. Hypertension is manifested in five syndromes [11], of which Qi-deficiency is only a minor one. The positive results from this trial were due to the fact that *A. senticosus*, an alternative Qi-tonic, was used [16].

Liang *et al.* [54] found that *P. notoginseng* improved endurance time to exhaustion and lowered mean blood pressure in 29 untrained young adults during an endurance exercise. *P. notoginseng* is another important ginseng species classified as homeostatic medicine to arrest bleeding and removes stagnant Xue.

#### **Conclusion**

Our analysis of 19 randomized controlled clinical trials of single herb ginseng shows that all the trials with both negative and positive results confirm the specific effects of ginseng indicated by Chinese medicine theory. Therefore, study designs guided by Chinese medicine theory are necessary to validate and improve future randomized controlled clinical trials in Chinese medicine.

#### **Competing interests**

The authors declare that they have no competing interests.

#### **Authors' contributions**

JY conceived the idea of the manuscript. VFE modified the idea and edited the manuscript. YXH and YJ collected references and participated in the discussions. WKG helped draft the manuscript. JY finalized the manuscript. All authors read and approved the final version of the manuscript.

#### **Acknowledgements**

We are grateful to the anonymous reviewers for their critical comments on this manuscript.

#### **References**

1. World Health Organization [<http://www.who.int/mediacentre/factsheets/fs134/en/>]
2. Hesketh T, Zhu WX: **Health in China. Traditional Chinese medicine: one country, two systems.** *Bmj* 1997, **315**:115-117.
3. Ernst E: **The role of complementary and alternative medicine.** *Bmj* 2000, **321**:1133-1135.
4. Normile D: **Asian medicine. The new face of traditional Chinese medicine.** *Science* 2003, **299**:188-190.
5. Xiang YZ, Shang HC, Gao XM, Zhang BL: **A comparison of the ancient use of ginseng in traditional Chinese medicine with modern pharmacological experiments and clinical trials.** *Phytther Res* 2008, **22**:851-858.
6. Vogler BK, Pittler MH, Ernst E: **The efficacy of ginseng. A systematic review of randomised clinical trials.** *Eur J Clin Pharmacol* 1999, **55**:567-575.
7. Shea JL: **Applying evidence-based medicine to traditional chinese medicine: debate and strategy.** *J Altern Complement Med* 2006, **12**:255-263.
8. De Smet PA: **Herbal remedies.** *N Engl J Med* 2002, **347**:2046-2056.
9. Li D: **Basic Theory of Traditional Chinese Medicine** 1st edition. Beijing: People's Medical Publishing House; 2006.
10. Ji S, Cheng Z: **Traditional Chinese Diagnostics** 1st edition. Beijing: People's Medical Publishing House; 2005.
11. Zou ZD, Liu N, Guo P, Guo LY, Sun Y, Shi J, Wang L: **[Analysis on clinical treatment in hypertension by traditional Chinese medicine for 10 years in Beijing].** *Zhongguo Zhong Yao Za Zhi* 2007, **32**:1569-1572.
12. Xu XY, Liu QR, Chen J: **[Clinical observation of Qi deficiency syndrome in 72 patients with chronic obstructive pulmonary disease treated with yiqi miyanji granule].** *Zhongguo Zhong Xi Jie He Za Zhi* 1996, **16**:81-83.
13. Wang XM, Yu RC, Wang YT: **[Study on advanced non-small cell lung cancer patients with Qi deficiency and blood stasis syndrome].** *Zhongguo Zhong Xi Jie He Za Zhi* 1994, **14**:724-726.
14. Li J, Zhang MZ, Chen BJ, et al.: **[Effect of tongguan capsule on post-intervention patients of coronary heart disease with qi deficiency and blood stasis syndrome].** *Zhongguo Zhong Xi Jie He Za Zhi* 2008, **28**:32-35.
15. Liu Q, Liu J, Liu D: **Clinical research into ke min yin for treatment of persistent allergic rhinitis in patients with qi deficiency and blood stasis.** *J Tradit Chin Med* 2003, **23**:106-108.
16. Huang Z: **Traditional Chinese Pharmacology** 1st edition. Beijing: People's Medical Publishing House; 2006.
17. Allen JD, McLung J, Nelson AG, Welsch M: **Ginseng supplementation does not enhance healthy young adults' peak aerobic exercise performance.** *J Am Coll Nutr* 1998, **17**:462-466.
18. Cardinal BJ, Engels HJ: **Ginseng does not enhance psychological well-being in healthy, young adults: results of a double-blind, placebo-controlled, randomized clinical trial.** *J Am Diet Assoc* 2001, **101**:655-660.
19. Engels HJ, Fahlman MM, Wirth JC: **Effects of ginseng on secretory IgA, performance, and recovery from interval exercise.** *Med Sci Sports Exerc* 2003, **35**:690-696.
20. Engels HJ, Kolokouri I, Cieslak TJ 2nd, Wirth JC: **Effects of ginseng supplementation on supramaximal exercise performance and short-term recovery.** *J Strength Cond Res* 2001, **15**:290-295.
21. Engels HJ, Wirth JC: **No ergogenic effects of ginseng (*Panax ginseng* C.A. Meyer) during graded maximal aerobic exercise.** *J Am Diet Assoc* 1997, **97**:1110-1115.

22. Gross D, Shenkman Z, Bleiberg B, Dayan M, Gittelson M, Efrat R: **Ginseng improves pulmonary functions and exercise capacity in patients with COPD.** *Monaldi Arch Chest Dis* 2002, **57**:242-246.
23. Kim JH, Park CY, Lee SJ: **Effects of sun ginseng on subjective quality of life in cancer patients: a double-blind, placebo-controlled pilot trial.** *J Clin Pharm Ther* 2006, **31**:331-334.
24. McElhaney JE, Gravenstein S, Cole SK, Davidson E, O'Neill D, Petitjean S, Rumble B, Shan JJ: **A placebo-controlled trial of a proprietary extract of North American ginseng (CVT-E002) to prevent acute respiratory illness in institutionalized older adults.** *J Am Geriatr Soc* 2004, **52**:13-19.
25. Predy GN, Goel V, Lovlin R, Donner A, Stitt L, Basu TK: **Efficacy of an extract of North American ginseng containing poly-furanosyl-pyranosyl-saccharides for preventing upper respiratory tract infections: a randomized controlled trial.** *Cmaj* 2005, **173**:1043-1048.
26. Sievenpiper JL, Arnason JT, Leiter LA, Vuksan V: **Decreasing, null and increasing effects of eight popular types of ginseng on acute postprandial glycemic indices in healthy humans: the role of ginsenosides.** *J Am Coll Nutr* 2004, **23**:248-258.
27. Sievenpiper JL, Arnason JT, Leiter LA, Vuksan V: **Null and opposing effects of Asian ginseng (*Panax ginseng* C.A. Meyer) on acute glycemia: results of two acute dose escalation studies.** *J Am Coll Nutr* 2003, **22**:524-532.
28. Sievenpiper JL, Sung MK, Di Buono M, Seung-Lee K, Nam KY, Arnason JT, Leiter LA, Vuksan V: **Korean red ginseng rootlets decrease acute postprandial glycemia: results from sequential preparation- and dose-finding studies.** *J Am Coll Nutr* 2006, **25**:100-107.
29. Sievenpiper JL, Arnason JT, Leiter LA, Vuksan V: **Variable effects of American ginseng: a batch of American ginseng (*Panax quinquefolius* L.) with a depressed ginsenoside profile does not affect postprandial glycemia.** *Eur J Clin Nutr* 2003, **57**:243-248.
30. Oka H, Yamamoto S, Kuroki T, Harihara S, Marumo T, Kim SR, Monna T, Kobayashi K, Tango T: **Prospective study of chemoprevention of hepatocellular carcinoma with Sho-saiko-to (TJ-9).** *Cancer* 1995, **76**:743-749.
31. Sheehan MP, Atherton DJ: **One-year follow up of children treated with Chinese medicinal herbs for atopic eczema.** *Br J Dermatol* 1994, **130**:488-493.
32. Sheehan MP, Atherton DJ: **A controlled trial of traditional Chinese medicinal plants in widespread non-exudative atopic eczema.** *Br J Dermatol* 1992, **126**:179-184.
33. Xue T, Roy R: **Studying traditional Chinese medicine.** *Science* 2003, **300**:740-741.
34. Wang W, Niu RJ: **[Effects of sheng mai injection on thoracoabdominal motion].** *Zhongguo Zhong Xi Yi Jie He Za Zhi* 1993, **13**:91-93.
35. Ding DZ, Shen TK, Cui YZ: **[Effects of red ginseng on the congestive heart failure and its mechanism].** *Zhongguo Zhong Xi Yi Jie He Za Zhi* 1995, **15**:325-327.
36. Xia ZY, Liu XY, Zhan LY, He YH, Luo T, Xia Z: **Ginsenosides compound (shen-fu) attenuates gastrointestinal injury and inhibits inflammatory response after cardiopulmonary bypass in patients with congenital heart disease.** *J Thorac Cardiovasc Surg* 2005, **130**:258-264.
37. Tian JZ, Zhu AH, Zhong J: **[A follow-up study on a randomized, single-blind control of King's Brain pills in treatment of memory disorder in elderly people with MCI in a Beijing community].** *Zhongguo Zhong Yao Za Zhi* 2003, **28**:987-991.
38. Hu JX, Jia GX, Yan ZR: **[Clinical and experimental study of shenshao tonguan pian in treating angina pectoris of coronary heart disease].** *Zhong Xi Yi Jie He Za Zhi* 1990, **10**:596-599.
39. Xie FY, Zeng ZF, Huang HY: **[Clinical observation on nasopharyngeal carcinoma treated with combined therapy of radiotherapy and ginseng polysaccharide injection].** *Zhongguo Zhong Xi Yi Jie He Za Zhi* 2001, **21**:332-334.
40. Siegel RK: **Ginseng abuse syndrome. Problems with the panacea.** *Jama* 1979, **241**:1614-1615.
41. Scaglione F, Cattaneo G, Alessandria M, Cogo R: **Efficacy and safety of the standardised Ginseng extract G115 for potentiating vaccination against the influenza syndrome and protection against the common cold [corrected].** *Drugs Exp Clin Res* 1996, **22**:65-72.
42. Caron MF, Hotsko AL, Robertson S, Mandybur L, Kluger J, White CM: **Electrocardiographic and hemodynamic effects of Panax ginseng.** *Ann Pharmacother* 2002, **36**:758-763.
43. Dowling EA, Redondo DR, Branch JD, Jones S, McNabb G, Williams MH: **Effect of *Eleutherococcus senticosus* on submaximal and maximal exercise performance.** *Med Sci Sports Exerc* 1996, **28**:482-489.
44. de Andrade E, de Mesquita AA, Claro Jde A, de Andrade PM, Ortiz V, Paranhos M, Srougi M: **Study of the efficacy of Korean Red Ginseng in the treatment of erectile dysfunction.** *Asian J Androl* 2007, **9**:241-244.
45. Hong B, Ji YH, Hong JH, Nam KY, Ahn TY: **A double-blind cross-over study evaluating the efficacy of korean red ginseng in patients with erectile dysfunction: a preliminary report.** *J Urol* 2002, **168**:2070-2073.
46. McElhaney JE, Goel V, Toane B, Hooten J, Shan JJ: **Efficacy of COLD-FX in the prevention of respiratory symptoms in community-dwelling adults: a randomized, double-blinded, placebo controlled trial.** *J Altern Complement Med* 2006, **12**:153-157.
47. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay HJ: **Assessing the quality of reports of randomized clinical trials: is blinding necessary?** *Control Clin Trials* 1996, **17**:1-12.
48. Ellis JM, Reddy P: **Effects of Panax ginseng on quality of life.** *Ann Pharmacother* 2002, **36**:375-379.
49. Stavro PM, Woo M, Leiter LA, Heim TF, Sievenpiper JL, Vuksan V: **Long-term intake of North American ginseng has no effect on 24-hour blood pressure and renal function.** *Hypertension* 2006, **47**:791-796.
50. Wiklund IK, Mattsson LA, Lindgren R, Limoni C: **Effects of a standardized ginseng extract on quality of life and physiological parameters in symptomatic postmenopausal women: a double-blind, placebo-controlled trial. Swedish Alternative Medicine Group.** *Int J Clin Pharmacol Res* 1999, **19**:89-99.
51. Zell B, Hirata J, Marcus A, Ettlinger B, Pressman A, Ettlinger KM: **Diagnosis of symptomatic postmenopausal women by traditional Chinese medicine practitioners.** *Menopause* 2000, **7**:129-134.
52. Cicero AF, Derosa G, Brillante R, Bernardi R, Nascetti S, Gaddi A: **Effects of Siberian ginseng (*Eleutherococcus senticosus* maxim.) on elderly quality of life: a randomized clinical trial.** *Arch Gerontol Geriatr Suppl* 2004:69-73.
53. Yin H: **Basic Theory of Traditional Chinese Medicine** 1st edition. Shanghai: Shanghai Scientific and Technical Publishers; 1991.
54. Liang MT, Podolka TD, Chuang WJ: **Panax notoginseng supplementation enhances physical performance during endurance exercise.** *J Strength Cond Res* 2005, **19**:108-114.

Publish with **BioMed Central** and every scientist can read your work free of charge

*"BioMed Central will be the most significant development for disseminating the results of biomedical research in our lifetime."*

Sir Paul Nurse, Cancer Research UK

Your research papers will be:

- available free of charge to the entire biomedical community
- peer reviewed and published immediately upon acceptance
- cited in PubMed and archived on PubMed Central
- yours — you keep the copyright

Submit your manuscript here:  
[http://www.biomedcentral.com/info/publishing\\_adv.asp](http://www.biomedcentral.com/info/publishing_adv.asp)

